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Background. Homologous down-regulation/desensitization
of the parathyroid hormone receptor (PTH1R)/adenylate cy-
clase system has been demonstrated in uremia, and may
contribute to parathyroid hormone (PTH) resistance; how-
ever, additional studies have shown that parathyroidectomy
fails to normalize the down-regulation of the PTH1R. The
present studies were designed to test directly, in vitro, the hy-
pothesis that factors circulating in the uremic environment,
other than PTH, decrease the response of osteoblastic cells to
PTH.
Methods. Studies were conducted in confluent cultures of
UMR 106–01 osteoblast-like cells. Uremic ultrafiltrate (UUF)
was obtained from patients on hemodialysis. Cells were exposed
to media containing 50% uremic ultrafiltrate for periods of
up to 72 hours. Control cultures were exposed to a buffered
salt solution containing a comparable ionic composition to
that of the UUF. PTH-stimulated cyclic adenosine monophos-
phate (cAMP) generation was determined by radioimmunoas-
say (RIA), PTH binding and PTH1R mRNA levels were
determined by radioligand binding and Northern analysis,
respectively.
Results. PTH-stimulated cAMP generation from cultures
treated with uremic ultrafiltrate for 48 hours was 1385.8 +/−
183.2 pmol/culture/5 minutes, whereas control cultures gener-
ated 2389.5 +/− 271 pmol cAMP/culture/5 minutes (P < 0.05).
PTH binding was decreased by 30% in cultures incubated with
UUF as compared to controls. The decrease in binding induced
by UUF was accompanied by a decrease in PTH1R mRNA
levels.
Conclusion. These findings demonstrate that factors present
in UUF decrease PTH-stimulated cAMP generation by a mech-
anism that involves a decrease in the levels of PTH1R mRNA
levels. Thus, the skeletal resistance to PTH in the setting of
chronic kidney disease, may be explained, at least in part, by
circulating factors other than PTH.
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Osteitis fibrosa cystica or high turnover renal osteodys-
trophy as a result of secondary hyperparathyroidism is
the most common skeletal abnormality found in pa-
tients on hemodialysis. Several factors contribute to the
pathogenesis of secondary hyperparathyroidism in pa-
tients with chronic kidney disease, including retention
of phosphorus, low levels of calcitriol, hypocalcemia,
abnormal parathyroid gland function, and skeletal re-
sistance to the actions of parathyroid hormone (PTH)
[1–4].
Homologous down-regulation of the PTH receptor
(PTH1R)/adenylate cyclase system has been implicated
as one of the factors contributing to PTH resistance,
and evidence suggests that decreased expression of the
PTH1R per se contributes to the decreased response
of target cells to PTH. Previous studies in our labora-
tory have demonstrated that exposure of UMR 106–01
osteoblast-like cells to PTH results in decreased cyclic
adenosine monophosphate (cAMP) response, decreased
receptor binding and decreased expression of PTH1R [5].
Studies in animals with chronic kidney disease have also
shown downregulation of PTH1R mRNA in rat femoral
bone and epiphyseal cartilage as well as in liver and
kidney tissue [6–9]. Further studies in rats with chronic
kidney disease demonstrating decreased PTH1 mRNA
levels in kidney have questioned the role of PTH in
the down-regulation of PTH1R since the defect was not
prevented or corrected by parathyroidectomy [8]. Stud-
ies in humans examining bone specimens from patients
with high turnover renal osteodystrophy have shown a
decrease in PTH1R mRNA in osteoblasts when com-
pared to patients with high bone turnover not related
to chronic kidney disease [10]. These observations sug-
gest that chronic kidney disease is associated with de-
creased expression of PTH1R; however, factors other
than parathyroid hormone may contribute to this ab-
normality. The present studies were designed to test the
direct effects of factors circulating in the uremic en-
vironment on PTH1R in UMR 106–01 osteoblast-like
cells.
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METHODS
Uremic ultrafiltrate
The studies were approved by the Saint Louis Univer-
sity Institutional Review Board. Informed consent was
obtained from each patient. Ultrafiltrate from uremic
plasma (UUF) was collected from 12 patients who were
stable on maintenance hemodialysis admitted to the hos-
pital for hemodialysis access-related procedures. Patients
were dialyzed with the same type of dialyzer (CA 210)
(Baxter, Deerfield, IL USA). The ultrafiltrates were col-
lected during the first 15 to 30 minutes after the initiation
of hemodialysis from the effluent side of the membrane
and were then submitted to ultrafiltration through 0.22 m
Vacuum Filter Unit (Costar, Cambridge, MA, USA). The
ultrafiltrates were then aliquoted and frozen at −80◦C un-
til the time of the study.
Cell culture
Studies were performed in cultures of UMR 106–01
osteoblast-like cells (Nicola Partridge, Robert Woods
Johnson Medical School, Piscataway, NJ, USA) be-
tween passages 14 and 24. Cells were grown to con-
fluence in minimum essential medium (MEM) supple-
mented with 5% fetal bovine serum (FBS), penicillin,
and streptomycin. Confluent cultures were then incu-
bated in medium containing 50% UUF for up to 72 hours.
Control cultures were incubated in medium containing
50% of Hanks’ balanced salt solution (HBSS) with a
comparable ionic composition. Electrolyte concentra-
tions in UUF (experimental) and HBSS (control) media
were sodium 135.1 +/− 2.23 and 141 mmol/L, potassium
4.8 +/− 0.97 and 5 mEq/L, ionized magnesium 0.53 +/−
0.07 and 0.61 mmol/L, and ionized calcium 1.17 +/− 0.10
and 1.25 mmol/L, respectively. For the experiments eval-
uating the direct effect of chronic exposure to PTH on
PTH-stimulated cAMP generation, synthetic rat PTH
[1–34] was added at the concentrations indicated for
48 hours.
PTH-stimulated cAMP production
The medium was aspirated from confluent cultures of
UMR 106–01 cells grown in 12-well plates. The cells were
washed three times with Krebs-Henseleit solution. PTH
was added at concentrations 10−8 mol/L for 5 minutes in
the presence of 1 mmol/L 3-isobutyl-1-methylxanthine
in 0.1% bovine serum albumin (BSA) in a total vol-
ume of 0.5 mL. The reactions were terminated with the
addition of 0.1 mL of 1.8 mol/L perchloric acid. After
5 minutes, the cell extracts were neutralized with 0.1 mL
of 3 mol/L KHCO3, the volume was brought to 1 mL with
20 mmol/L MES (2-[n-morpholino] ethanesulfonic acid),
pH 6.2, and cAMP was measured by radioimmunoassay
(RIA) as previously described [11].
Iodination of PTH
Five micrograms of Nle8,21Tyr34-rat PTH [1-34]NH2
were iodinated with 25 g of chloramine T in the pres-
ence of 2 mCi of 125I. The reaction was terminated with
75 g of sodium metabisulfite and 0.5 mL of 20% ace-
tonitrile (ACN) in 0.1% trifluoroacetic acid (TFA) was
added. This was applied to a C18 SepPak, which had been
equilibrated sequentially with 3 mL of 100% ACN, 5 mL
of 80% ACN, 0.1% TFA, and finally with 5 mL of 20%
ACN, 0.1% TFA. Following application of the iodination
reaction, the cartridge was washed with 2.5 mL of 20%
ACN, 0.1% TFA, and the iodinated hormone was eluted
with three successive 0.5 mL aliquots of 50% ACN, 0.1%
TFA. The peak tube was diluted in 1% BSA and aliquots
were stored at −80◦C.
PTH binding studies
The medium was removed from confluent cultures of
UMR106–01 cells, and the cells were washed twice with
MEM containing 5% FBS at 10◦C. Following addition
of 10−6 mol/L PTH to duplicate wells for determination
of nonspecific binding, 5 × 104 cpm of 125I Nle8,21Tyr34-
rat PTH [1-34]NH2 were added to all wells. Incuba-
tions were continued for 3 hours at 10◦C. The cells were
then washed three times with cold MEM-5%FBS and
phosphate-buffered saline (PBS). The cells were solubi-
lized in 0.1 mol/L sodium hydroxide and the radioactivity
was then quantitated.
PTH1R mRNA levels
Total RNA was isolated from cultured cells using
the TRIzol method as described by the manufacturer
(Life Technologies, Grand Island, NY, USA). PTH1R
mRNA levels were determined by Northern analysis us-
ing a probe consisting of nucleotides 439 to 768 of the
rat PTH1R cDNA prepared by reverse transcription-
polymerase chain reaction (RT-PCR) from rat kidney
RNA, cloned into pCRII and sequenced to confirm
identity with the published sequence of the cloned rat
PTH/PTHrP receptor [5]. Using 20 lg of total RNA,
Northern analysis was performed using Northern Max-
GlyTM Kit as described by the manufacturer (Am-
bion, Austin, TX, USA). All reagents mentioned in the
following procedure were obtained from Ambion un-
less otherwise specified. Briefly, 20 lg of total RNA
was mixed 1:1 with glyoxal load dye and the mix-
ture was incubated for 30 minutes in a 50◦C water
bath. The samples were then applied to 1% agarose
LE gel and electrophoresed at 100 volts for 1 hour.
After transferring to nylon membranes, the RNA was
bound by ultraviolet cross-linking (Stratalinker) (Strate-
gene Cloning systems, La Jolla, CA, USA). The fil-
ters were prehybridized for 1 hour at 42◦C in Ultrahyb
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solution. The filters were probed with 32P-deoxycytidine
5′triphosphate radiolabeled PTHR1 cDNA for 16 to
20 hours (Megaprime) (Amersham Life Science, Ar-
lington Heights, IL, USA), washed with low strin-
gency solution for 10 minutes at 42◦C. The filters
were analyzed by phosphorimager (Molecular Dynam-
ics, Sunnyvale, CA, USA). After analysis, the filters were
then stripped and reprobed with radiolabeled cDNA for
glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
The PTH1R bands were normalized relative to the
GAPDH band using Image Quant software.
Intact PTH assays
Intact PTH levels in UUF and serum were measured
by two-site immunoradiometric assay (IRMA) (Nichols,
San Juan Capistrano, CA, USA). The procedures were
performed according to the manufacturer’s instructions.
Calculations
Statistical analyses were performed using Student
t test. Analysis of variance (ANOVA) was used when mul-
tiple groups were being analyzed. Differences between
groups were considered significant when P < 0.05. Data
are expressed as mean +/− standard error of the mean.
RESULTS
Effect of UUF on PTH-stimulated cAMP generation
We first determined the effect of individual UUFs
obtained from each of 12 patients on both basal and
PTH-stimulated cAMP response in confluent cultures of
UMR106–01 osteoblast-like cells. As shown in Figure 1,
following a 48-hour incubation with UUF, the ability of
the cells to respond to acute stimulation with PTH was
impaired without significant difference in basal cAMP
levels. In cultures treated with UUF, the values for PTH-
stimulated cAMP generation were 42.6 +/− 2.7% lower
as compared to the values obtained in control cultures
(P < 0.01). This degree of suppression was similar for
all UUF samples and was not influenced by the concen-
tration of intact PTH in serum, which ranged from 18 to
1465 pg/mL. Figure 2 shows the time course for the effect
of UUF on PTH-stimulated cAMP generation. The sup-
pression of PTH-stimulated cAMP generation was evi-
dent at 24 hours and reached statistical significance at
48 hours (P < 0.01 as compared to time 0). No further
effect was noted after 72 hours of incubation with UUF.
Cell viability was not significantly different in control vs.
UUF-treated cultures as determined by protein content
(data not shown).
Intact PTH levels in UUF and effect on PTH-stimulated
cAMP generation
In order to exclude the possibility that the impaired re-
sponse to PTH as a result of exposure to UUF was due to
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Fig. 1. Effect of uremic ultrafiltrate (UUF) on basal and parathyroid
hormone (PTH)-stimulated cyclic adenosine monophosphate (cAMP)
generation. Confluent cultures of UMR 106–01 cells were incubated in
the presence () or absence () of UUF for 48 hours prior to acute
stimulation with PTH (10−8 mol/L). PTH-stimulated cAMP generation
was measured by radioimmunoassay (RIA). The values represent the
mean ± SEM from 12 different samples.
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Fig. 2. Time course of the effect of uremic ultrafiltrate (UUF) on
parathyroid hormone (PTH)-stimulated cyclic adenosine monophos-
phate (cAMP) generation. Confluent cultures of UMR 106–01 cells
were exposed to UUF for the times indicated prior to acute stimulation
with PTH (10−8 mol/L). PTH-stimulated cAMP generation was mea-
sured by radioimmunoassay (RIA). The values represent the mean ±
SEM from four different samples. ∗P < 0.01 as compared to time 0.
homologous down-regulation of the PTH1R due to the
presence of PTH in the UUF, we measured the concen-
tration of intact PTH in the UUF. The values ranged from
6 to 79 pg/mL; therefore, the concentration of intact PTH
in the media containing 50% UUF used for the present
studies ranged from 3 to 40 pg/mL. Thus, we exposed
UMR 106–01 cells to equimolar amounts of the hormone
(10−12 to 10−11 mol/L) for 48 hours. As shown in Figure 3,
chronic exposure of the cultures to PTH at concentrations
similar to those of intact PTH present in UUF did not
have an effect on cAMP accumulation following acute
stimulation with PTH. These findings indicate that fac-
tors present in UUF, other than PTH, are responsible
for the impaired ability of the cells to respond to PTH
stimulation.
Effect of UUF on PTH binding
In order to determine if the inhibitory effect of UUF
on PTH-stimulated cAMP generation was due to a defect
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Fig. 3. Effect of chronic exposure to parathyroid hormone (PTH) con-
centrations present in uremic ultrafiltrate UUF on PTH-stimulated
cyclic adenosine monophosphate (cAMP) generation. Confluent cul-
tures of UMR 106–01 cells were exposed to PTH 10−12, 10−11,
and 10−10 mol/L for 48 hours prior to acute stimulation with PTH
(10−8 mol/L). The values represent the mean ± SEM from four dif-
ferent experiments.
in PTH binding to its receptor, we examined the effect of
UUF on 125I-PTH binding in confluent cultures of UMR
106–01 cells. As shown in Figure 4, exposure to UUF
for 48 hours resulted in a 30% decrease in PTH binding
as compared to control cultures (P < 0.05). Competitive
inhibition binding experiments revealed that binding was
decreased at all concentrations of unlabeled PTH tested.
Scatchard analysis indicated that the decrease in binding
was due to a decrease in receptor number with no change
in receptor affinity.
Effect of UUF on PTH1R mRNA
We next examined whether the decrease in PTH bind-
ing in response to exposure to UUF was related to a de-
crease in PTH1R mRNA levels. The effect of UUF on
the levels of PTH1R mRNA levels was determined by
Northern analysis and corrected for GAPDH mRNA. As
shown in Figure 5, exposure to UUF for 12 hours results
in a 56.2 +/− 5.9% decrease in PTH1R mRNA levels
(P < 0.05 as compared to time 0). The effect of UUF on
PTH1R mRNA peaked at 48 hours when the levels had
decreased by 62.3 +/− 5.7% (P < 0.05 as compared to
time 0), and no further decrease was noted after 72 hours
of exposure.
DISCUSSION
Previous studies have demonstrated that high
circulating levels of PTH may lead to homologous down-
regulation/desensitization of the PTH1R/adenylate
cyclase system thus leading to PTH resistance. Studies
in our laboratory have shown that PTH directly de-
creases the expression of PTH1R in osteoblastic cells
[5]. Consistent with our findings in vitro, studies in
uremic animals have also shown decreased expression of
PTH1R in target tissues [7–9, 12]. Interestingly, however,
Uren˜a et al [8] reported that parathyroidectomy failed
to prevent the downregulation of PTH1R in rats with
chronic kidney disease. These findings suggest that in
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Fig. 4. Competitive inhibition of equilibrium binding of 125I
Nle8,21Tyr34-rat PTH [1-34]NH2. Confluent cultures of UMR 106–01
cells were incubated in the presence () or absence () of uremic ul-
trafiltrate (UUF) for 48 hours. Binding of 125I Nle8,21Tyr34-rat PTH
[1-34]NH2 was examined in the presence of increasing concentrations
of unlabeled parathyroid hormone (PTH). The inset shows a Scatchard
analysis of the data.
addition to PTH, there are other factors circulating
in the uremic environment that may account for the
down-regulation of PTH1R. The present studies show
that exposure of UMR 106–01 osteoblast-like cells to
UUF obtained from patients on hemodialysis results in
impaired PTH-stimulated cAMP generation as well as
decreased PTH binding. The decrease in PTH binding
was due to decreased PTH1R number by a mechanism
involving a decrease in steady-state levels of PTH1R
mRNA. This effect is due to factors present in the uremic
environment other than PTH.
Skeletal resistance to PTH in the setting of chronic
kidney disease was initially described by Evanson [13].
Subsequently, Llach et al [14] found a delayed recovery
from ethylenediaminetetraacetic acid (EDTA)-induced
hypocalcemia in patients with renal failure despite high
levels of PTH. Massry et al [15] demonstrated a reduced
calcemic response to infusion of parathyroid extract to
105 subjects with varying degrees of renal failure. A
diminished calcemic response to PTH in chronic kid-
ney disease has also been demonstrated in animal stud-
ies [16–24], and using dogs with chronic kidney disease,
Galceran et al [24] found that the calcemic response to
PTH was restored following parathyroidectomy. Further-
more, a blunted cAMP response to PTH extract was ob-
served by Olgaard et al [25] in isolated perfused bones
obtained from uremic dogs.
The mechanisms responsible for PTH resistance in ure-
mia remain unclear. It is well accepted that exposure to
PTH results in homologous desensitization and down-
regulation of the PTH1R/adenylate cyclase system [5,
26–36], and recovery from this phenomenon has been
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Fig. 5. Effect of uremic ultrafiltrate (UUF) on parathyroid hormone
receptor (PTH1R) mRNA levels. Confluent cultures of UMR 106–01
cells were exposed to UUF for the times indicated. Total RNA was
isolated and PTH1R mRNA levels were determined by Northern anal-
ysis. The membranes were stripped and reprobed using a cDNA for
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (A). Densito-
metric analysis of the levels of PTH1R mRNA corrected for GAPDH
mRNA (B). The values represent the mean ± SEM from five different
samples. ∗P < 0.01.
observed following withdrawal of the hormone [28, 29].
We have previously shown that PTH directly down-
regulates its own receptor in UMR 106–01 osteoblast
like-cells by a mechanism that involves decreased PTH1R
mRNA levels [5]. These findings are in agreement with
studies in experimental animals with secondary hyper-
parathyroidism related to chronic kidney disease and sug-
gest that decreased expression of PTH1R in this setting
is a result of increased circulating levels of PTH [6, 7,
9]. However, several lines of evidence indicate that there
may be additional circulating factors in the uremic en-
vironment that contribute to decreased PTH1R expres-
sion. In this regard, Uren˜a et al [8] found a decrease in
PTH1R mRNA in liver and kidney of uremic rats; how-
ever, parathyroidectomy did not prevent the downregula-
tion of the receptor. Tian et al [9] showed partial normal-
ization of the PTH1R mRNA levels in tissues of uremic
rats after parathyroidectomy. Thus, although chronic ex-
posure to PTH in the setting of chronic kidney disease
can certainly decrease the expression of PTH1R, these
data, as well as the present studies, suggest that other fac-
tors present in the uremic milieu may also be involved in
this process.
In skeletal tissue, PTH1R mRNA levels have been
found to be decreased in bone and epiphyseal cartilage
growth plate of uremic rats. Recent studies by Picton
et al [10] have provided additional insight into the cel-
lular mechanism of skeletal resistance to PTH in the set-
ting of chronic kidney disease. The investigators used in
situ hybridization in order to examine PTH1R mRNA ex-
pression in bone biopsy specimens obtained from patients
with abnormalities of bone turnover. The groups included
patients with high and low turnover renal bone disease,
high turnover bone disease in patients with normal renal
function such as Pagetic bone, and normal controls. The
studies showed that the expression of PTH1R mRNA in
osteoblasts from patients with high turnover renal bone
disease was only 36% of that found in Paget’s disease and
51% of that found in normal bone. Also, the osteoblas-
tic PTH1R mRNA signal from adynamic bone was only
28% of that of normal bone. In addition, there was no cor-
relation between the expression of PTH1R mRNA and
serum PTH levels. Therefore, studies in experimental an-
imals as well as in humans indicate that PTH levels are
not the sole factor involved in down-regulation of PTH1R
expression in the setting of chronic kidney disease. The
present studies further support such concept and point
toward dialyzable uremic factors as playing a role in this
process.
The precise nature of the uremic factors involved in
the down-regulation of PTH receptors is not clear at the
present time. A variety of cytokines and growth factors
are known to down-regulate the PTH1R/adenylate cy-
clase system. Evidence suggests that uremia is an inflam-
matory state with up-regulation of multiple cytokines, es-
pecially tumor necrosis factor (TNF) and interleukin-1
(IL-1) [37–39], which have both been shown to affect the
PTH1R/adenylate cyclase system. Katz et al [40] demon-
strated that exposure of UMR 106–01 osteoblast-like
cells to TNF-a and IL-1 inhibited PTH-sensitive adeny-
late cyclase secondary to a decline in PTH receptor den-
sity. Schneider et al [41] showed that incubation of UMR
106–01 osteoblast-like cells with TNF-a lead to a de-
crease in PTH binding to its receptor which was due to
a decrease in receptor number [41]. The effect of TNF-a
to inhibit the PTHR1/adenylate cyclase system has also
been demonstrated by other investigators [42–44]. In ad-
dition to TNF-a and IL-1, interferon-a, and TGF-b have
also been shown to inhibit the expression of PTH1R in
osteoblastic cells [45, 46]. Thus, it is possible that the pres-
ence of these or a variety of other cytokines in UUF may
contribute to the down-regulation of the PTH1 receptor
observed in our studies.
Factors present in the uremic environment have been
described to affect other cellular processes, which are
likely to have an impact on skeletal biology. For example,
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it is well accepted that calcitriol resistance is present in
uremia, and evidence suggests that uremic toxins are also
involved in this process [47–51]. In this regard, studies by
Patel et al [51] have shown that UUF obtained from pa-
tients on hemodialysis decreases the binding of the vita-
min D receptor to the vitamin D responsive elements in
target genes, thus leading to impaired calcitriol-mediated
gene transcription. These findings offer an explanation
for the calcitriol resistance observed in the setting of ure-
mia. More recently, Canalejo et al [52] reported that UUF
obtained from patients on hemodialysis prevented the ef-
fect of calcitriol to inhibit parathyroid cell proliferation.
CONCLUSION
We have shown that UUF obtained from patients
on hemodialysis contains factors that decrease PTH-
stimulated cAMP generation in UMR 106–01 osteoblast-
like cells. The impaired response to PTH was not re-
lated to homologous down-regulation/desensitization of
the PTH1R/adenylate cyclase system since preincubation
of the cells with concentrations of PTH similar to those
present in UUF did not have an effect on cAMP accumu-
lation following acute stimulation with PTH. In addition,
we have shown that UUF decreases PTH receptor num-
ber by a mechanism involving decreased PTH1R mRNA.
These findings suggest that circulating uremic factors may
contribute to skeletal resistance to PTH in the setting of
chronic kidney disease.
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